China unveils GMP requirements
This article was originally published in The Silver Sheet
Executive Summary
Device manufacturers in China will be required to establish quality control systems under new good manufacturing practice (GMP) requirements issued by the country's State Food and Drug Administration (SFDA). The GMP interim requirements were posted on SFDA's Web site Dec. 30, along with a separate document on GMP inspections, which requires companies to file applications before facility inspections are conducted. According to an unofficial translation, provincial SFDA offices will examine GMP documents submitted by higher-risk Class II and Class III device manufacturing facilities and, in the case of Class III devices, forward an opinion to the central SFDA, which will then complete a review of the materials within 10 days. Onsite factory inspections will be performed either by the provincial SFDA offices or the central SFDA. Firms will be notified of an upcoming inspection five days ahead of time, with inspections generally expected to last two or three working days, according to the unofficial translation provided by the law firm Foley & Lardner. The rules will become effective Jan. 1, 2011
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.